Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Conditions:   Clinical Stage II Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Esophageal Adenocarcinoma AJCC v8;   Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8;   Clinical Stage IV Esophageal Adenocarcinoma AJCC v8;   Clinical Stage IV Gastroesophageal Junction Adenocarcin oma AJCC v8;   Locally Advanced Esophageal Adenocarcinoma;   Locally Advanced Gastroesophageal Junction Adenocarcinoma;   Metastatic Esophageal Adenocarcinoma;   Metastatic Gastroesophageal Junction Adenocarcinoma;   Unresectable Esophageal Adenocarcinoma;   Unresectable Gastroesophagea l Junction Adenocarcinoma Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Drug: Fluorouracil;   Drug: Leucovorin;   Drug: Oxaliplatin;   Biological: Pembrolizumab;   Drug: Propranolol Hydrochloride;   Other: Questionnaire Administration Sponsors:   Roswell Park Cancer Institute;   United States Department of Defense Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials